rs73467954
Variant names: 
Your query was ambiguous. Multiple possible variants found: 
Variant summary
Our verdict is Benign. The variant received -21 ACMG points: 0P and 21B. BP4_StrongBP6_Very_StrongBP7BS1BS2
The NM_033305.3(VPS13A):c.5184T>C(p.Ser1728Ser) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000685 in 1,613,886 control chromosomes in the GnomAD database, including 5 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).
Frequency
 Genomes: 𝑓 0.0037   (  3   hom.,  cov: 32) 
 Exomes 𝑓:  0.00037   (  2   hom.  ) 
Consequence
 VPS13A
NM_033305.3 synonymous
NM_033305.3 synonymous
Scores
 2
Clinical Significance
Conservation
 PhyloP100:  -0.171  
Publications
0 publications found 
Genes affected
 VPS13A  (HGNC:1908):  (vacuolar protein sorting 13 homolog A) The protein encoded by this gene may control steps in the cycling of proteins through the trans-Golgi network to endosomes, lysosomes and the plasma membrane. Mutations in this gene cause the autosomal recessive disorder, chorea-acanthocytosis. Alternative splicing of this gene results in multiple transcript variants. [provided by RefSeq, Jul 2008] 
VPS13A Gene-Disease associations (from GenCC):
- chorea-acanthocytosisInheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Orphanet, Genomics England PanelApp, Ambry Genetics, Labcorp Genetics (formerly Invitae)
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -21 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.62). 
BP6
Variant 9-77318462-T-C is Benign according to our data. Variant chr9-77318462-T-C is described in ClinVar as Benign. ClinVar VariationId is 448866.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. 
BP7
Synonymous conserved (PhyloP=-0.171 with no splicing effect.
BS1
Variant frequency is greater than expected in population afr. GnomAd4 allele frequency = 0.00366 (557/152308) while in subpopulation AFR AF = 0.0128 (530/41566). AF 95% confidence interval is 0.0119. There are 3 homozygotes in GnomAd4. There are 268 alleles in the male GnomAd4 subpopulation. Median coverage is 32. This position passed quality control check. 
BS2
High Homozygotes in GnomAd4 at 3 AR gene
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt | 
|---|---|---|---|---|---|---|---|---|
| VPS13A | NM_033305.3 | c.5184T>C | p.Ser1728Ser | synonymous_variant | Exon 41 of 72 | ENST00000360280.8 | NP_150648.2 | |
| VPS13A | NM_001018037.2 | c.5067T>C | p.Ser1689Ser | synonymous_variant | Exon 40 of 71 | NP_001018047.1 | ||
| VPS13A | NM_015186.4 | c.5184T>C | p.Ser1728Ser | synonymous_variant | Exon 41 of 69 | NP_056001.1 | ||
| VPS13A | NM_001018038.3 | c.5184T>C | p.Ser1728Ser | synonymous_variant | Exon 41 of 69 | NP_001018048.1 | 
Ensembl
Frequencies
GnomAD3 genomes  0.00365  AC: 555AN: 152190Hom.:  3  Cov.: 32 show subpopulations 
GnomAD3 genomes 
 AF: 
AC: 
555
AN: 
152190
Hom.: 
Cov.: 
32
Gnomad AFR 
 AF: 
Gnomad AMI 
 AF: 
Gnomad AMR 
 AF: 
Gnomad ASJ 
 AF: 
Gnomad EAS 
 AF: 
Gnomad SAS 
 AF: 
Gnomad FIN 
 AF: 
Gnomad MID 
 AF: 
Gnomad NFE 
 AF: 
Gnomad OTH 
 AF: 
GnomAD2 exomes  AF:  0.000903  AC: 226AN: 250194 AF XY:  0.000651   show subpopulations 
GnomAD2 exomes 
 AF: 
AC: 
226
AN: 
250194
 AF XY: 
Gnomad AFR exome 
 AF: 
Gnomad AMR exome 
 AF: 
Gnomad ASJ exome 
 AF: 
Gnomad EAS exome 
 AF: 
Gnomad FIN exome 
 AF: 
Gnomad NFE exome 
 AF: 
Gnomad OTH exome 
 AF: 
GnomAD4 exome  AF:  0.000375  AC: 548AN: 1461578Hom.:  2  Cov.: 31 AF XY:  0.000337  AC XY: 245AN XY: 727094 show subpopulations 
GnomAD4 exome 
 AF: 
AC: 
548
AN: 
1461578
Hom.: 
Cov.: 
31
 AF XY: 
AC XY: 
245
AN XY: 
727094
show subpopulations 
African (AFR) 
 AF: 
AC: 
409
AN: 
33456
American (AMR) 
 AF: 
AC: 
33
AN: 
44702
Ashkenazi Jewish (ASJ) 
 AF: 
AC: 
0
AN: 
26124
East Asian (EAS) 
 AF: 
AC: 
0
AN: 
39662
South Asian (SAS) 
 AF: 
AC: 
2
AN: 
86244
European-Finnish (FIN) 
 AF: 
AC: 
0
AN: 
53412
Middle Eastern (MID) 
 AF: 
AC: 
0
AN: 
5760
European-Non Finnish (NFE) 
 AF: 
AC: 
64
AN: 
1111832
Other (OTH) 
 AF: 
AC: 
40
AN: 
60386
 Allele Balance Distribution 
 Red line indicates average allele balance 
 Average allele balance: 0.492 
Heterozygous variant carriers
 0 
 34 
 69 
 103 
 138 
 172 
 0.00 
 0.20 
 0.40 
 0.60 
 0.80 
 0.95 
Allele balance
Age Distribution
Exome Het
Exome Hom
Variant carriers
 0 
 20 
 40 
 60 
 80 
 100 
 <30 
 30-35 
 35-40 
 40-45 
 45-50 
 50-55 
 55-60 
 60-65 
 65-70 
 70-75 
 75-80 
 >80 
Age
GnomAD4 genome  0.00366  AC: 557AN: 152308Hom.:  3  Cov.: 32 AF XY:  0.00360  AC XY: 268AN XY: 74482 show subpopulations 
GnomAD4 genome 
 AF: 
AC: 
557
AN: 
152308
Hom.: 
Cov.: 
32
 AF XY: 
AC XY: 
268
AN XY: 
74482
show subpopulations 
African (AFR) 
 AF: 
AC: 
530
AN: 
41566
American (AMR) 
 AF: 
AC: 
21
AN: 
15300
Ashkenazi Jewish (ASJ) 
 AF: 
AC: 
0
AN: 
3470
East Asian (EAS) 
 AF: 
AC: 
0
AN: 
5188
South Asian (SAS) 
 AF: 
AC: 
0
AN: 
4832
European-Finnish (FIN) 
 AF: 
AC: 
0
AN: 
10614
Middle Eastern (MID) 
 AF: 
AC: 
0
AN: 
294
European-Non Finnish (NFE) 
 AF: 
AC: 
2
AN: 
68018
Other (OTH) 
 AF: 
AC: 
4
AN: 
2114
 Allele Balance Distribution 
 Red line indicates average allele balance 
 Average allele balance: 0.503 
Heterozygous variant carriers
 0 
 26 
 53 
 79 
 106 
 132 
 0.00 
 0.20 
 0.40 
 0.60 
 0.80 
 0.95 
Allele balance
Age Distribution
Genome Het
Variant carriers
 0 
 10 
 20 
 30 
 40 
 50 
 <30 
 30-35 
 35-40 
 40-45 
 45-50 
 50-55 
 55-60 
 60-65 
 65-70 
 70-75 
 75-80 
 >80 
Age
Alfa 
 AF: 
Hom.: 
Bravo 
 AF: 
Asia WGS 
 AF: 
AC: 
3
AN: 
3478
EpiCase 
 AF: 
EpiControl 
 AF: 
ClinVar
Significance: Benign 
Submissions summary: Benign:4 
Revision: criteria provided, multiple submitters, no conflicts
LINK: link 
Submissions by phenotype
not provided    Benign:2 
-
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided
- -
Jan 24, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing
- -
not specified    Benign:1 
Mar 29, 2017
Athena Diagnostics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing
- -
Chorea-acanthocytosis    Benign:1 
Dec 06, 2019
Natera, Inc.
Significance:Likely benign
Review Status:no assertion criteria provided
Collection Method:clinical testing
- -
Computational scores
Source: 
Name
Calibrated prediction
Score
Prediction
 BayesDel_noAF 
 Benign 
 DANN 
 Benign 
 PhyloP100 
Splicing
Name
Calibrated prediction
Score
Prediction
 SpliceAI score (max) 
Details are displayed if max score is > 0.2
 Find out detailed SpliceAI scores and Pangolin per-transcript scores at 
Publications
 You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.